InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,738.17
(
-0.13%
)
US TECH 100
19,436.00
(
-0.73%
)
Dow Jones
42,313.00
(
0.33%
)
Brent Oil
72.01
(
0.00%
)
Bitcoin
65,584.33
(
-0.31%
)
Post# of 253250
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

flatlander_60048

Send PM Follow Ignore
Followers 10
Posts 478
Boards Moderated 0
Alias Born 02/10/2006

flatlander_60048

Re: DewDiligence post# 195706

Tuesday, 10/06/2015 5:25:43 PM

Tuesday, October 06, 2015 5:25:43 PM

Post# of 253250
GHDX was down 11% at one point possibly coincidental with Exas and/or ILMN (reduced genetic testing reimbursement) or overall biotech weakness.

Urology Review suggests that the Prostate test which recently received CMS billing code last month could fill a very unmet need.

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4274174/

Looks like the diagnostic stocks that never had the run up are getting tarred with the same brush being used on the rest of biotech.


FL
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up